10-K: BioRestorative Therapies Issues 10-K Filing, Outlines Progress in Disc/Spine and ThermoStem Programs

BioRestorative Therapies files its 10-K, highlighting clinical trial progress, financial results, and future plans in cell therapy.

Summary

• BioRestorative Therapies, Inc., a Nevada corporation, develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.
• The company is pursuing its Disc/Spine Program with BRTX-100, which has received FDA authorization for a Phase 2 clinical trial to treat chronic lower back pain arising from degenerative disc disease.
• They have commenced the Phase 2 clinical trial through various agreements and lab expansions.
• BioRestorative is also developing its ThermoStem Program, a pre-clinical program using brown adipose (fat) for cell-based treatment of type 2 diabetes, obesity, and other metabolic disorders.
• The company operates a commercial biocosmeceuticals business, selling a cell-based secretome containing exosomes, proteins, and growth factors.
• In February 2024, BioRestorative issued 2,000,000 shares of common stock pursuant to the exercise of warrants, receiving gross proceeds of approximately $8,100,000.
• In November 2024, the company entered into an At The Market Offering Agreement with Rodman & Renshaw LLC, potentially offering and selling shares of common stock up to approximately $3.6 million.
• As of March 26, 2025, there were 7,504,780 shares of common stock outstanding.
• The company's current funds may not be sufficient to complete the Phase 2 clinical trial, continue pre-clinical research, and satisfy working capital needs through the next 12 months.
• The company intends to seek additional financing through various means, but there is no assurance that it will be obtained on commercially reasonable terms.
• As of December 31, 2024, the company's accumulated deficit was $155,678,715.
• For the year ended December 31, 2024, the company had a net loss of $9.0 million and negative cash flows from operations of $8.2 million.
• The report of the independent registered public accounting firm expresses substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and partnerships, the financial situation raises significant concerns about the company's long-term viability. The auditor's going concern warning is a major red flag.

Positives

• FDA authorization for Phase 2 clinical trial of BRTX-100.
• Development of ThermoStem Program with issued patents.
• Commercial biocosmeceuticals business generating revenue.
• Receipt of $8.1 million in gross proceeds from warrant exercises in February 2024.
• Exclusive supply agreement with Cartessa Aesthetics, LLC for cell-based biologic serum.
• Provisional license from the New York State Department of Health for processing allogeneic donor tissue material for medical research.

Negatives

• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company's current funds may not be sufficient to complete the Phase 2 clinical trial, continue pre-clinical research, and satisfy working capital needs through the next 12 months.
• As of December 31, 2024, the company's accumulated deficit was $155,678,715.
• For the year ended December 31, 2024, the company had a net loss of $9.0 million and negative cash flows from operations of $8.2 million.
• The company has not generated any significant revenues to date.

Risks

• The company's limited operating history and substantial losses since inception raise concerns about its ability to continue as a going concern.
• The company needs to obtain significant additional financing to complete clinical trials and implement its business plan.
• The company's future success is significantly dependent on the timely and successful development and commercialization of BRTX-100.
• The company may experience delays and other difficulties in enrolling a sufficient number of patients in its clinical trials.
• The development of cell therapy product candidates is subject to uncertainty because autologous cell therapy is inherently variable.
• The company may never obtain FDA approval for any of its product candidates.
• The company presently lacks manufacturing capabilities to produce its product candidates at commercial scale quantities.
• The commercial potential and profitability of the company's products are unknown and subject to significant risk and uncertainty.
• The company is vulnerable to competition and technological change.
• The company may be subject to significant product liability claims and litigation.
• The company's inability to obtain reimbursement for its products and services from private and governmental insurers could negatively impact demand for its products and services.

Future Outlook

The company anticipates continuing to incur net losses and negative cash flows from operations as it executes its development plans for 2025 and beyond, and believes it may not have sufficient cash for at least twelve months after the issuance date of the financial statements included in this Annual Report which raises substantial doubt about its ability to continue as a going concern.

Industry Context

The company operates in the rapidly progressing regenerative medicine field, competing with pharmaceutical, biotechnology, and medical device companies. The recent extensive use of both FDA-approved and compounded versions of glucagon-like peptide-1 (GLP-1) receptor agonist drug products, such as Wegovy and Ozempic (semaglutide) for the treatment of obesity has significantly increased the competition in the obesity market.

Comparison to Industry Standards

• The document compares BRTX-100 to Mesoblast's adult stem cell biologic, highlighting potential competitive advantages such as the use of autologous cells, hypoxic culturing, and autologous platelet lysate.
• The document notes that clinical studies of therapies comparative to BRTX-100 have shown reduced pain, increased function, and an absence of significant safety issues with a durable response.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and dependence on future financing.
• Employees' job security is uncertain given the going concern warning.
• Customers may be affected by potential disruptions in product development and availability.
• Suppliers and creditors face increased risk of non-payment.
• The company's ability to execute its business plan and deliver value to stakeholders is contingent on securing additional funding.

Next Steps

• Continue Phase 2 clinical trial for BRTX-100.
• Undertake additional preclinical animal studies in order to optimize delivery and explore the feasibility of targeting additional indications for ThermoStem Program.
• Explore the potential of expanding commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies.

Key Dates

Keywords

BRTX-100, ThermoStem, cell therapy, clinical trial, regenerative medicine, biocosmeceuticals, stem cells, biologics, FDA, spine, disc, obesity, diabetes